3 results match your criteria: "j Dip. Medicina-Università Campus Bio-Medico[Affiliation]"
Poliprotect vs Omeprazole in the Relief of Heartburn, Epigastric Pain, and Burning in Patients Without Erosive Esophagitis and Gastroduodenal Lesions: A Randomized, Controlled Trial.
Am J Gastroenterol
November 2023
Dipartimento di Medicina Traslazionale e di Precisione, Sapienza University of Rome, Rome, Italy.
Article Synopsis
- Poliprotect (a mucosal protective agent) was found to be just as effective as omeprazole for treating heartburn and epigastric pain in patients without visible esophageal damage.
- In a 4-week study, 275 participants were treated with either omeprazole or Poliprotect, with Poliprotect showing similar symptom relief and no significant changes in gut microbiota.
- No serious side effects occurred in either treatment group, suggesting Poliprotect is a safe alternative for patients who cannot take proton-pump inhibitors like omeprazole.
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies.
Br J Haematol
November 2021
University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis.
View Article and Find Full Text PDFIntroduction: In spite of the proven efficacy of the tyrosine kinase inhibitor (TKI), imatinib, in chronic myeloid leukemia (CML), many patients develop intolerance and discontinue therapy in the long-term. Second-generation TKIs (dasatinib, nilotinib, bosutinib) and the third-generation TKI, ponatinib, have added opportunities but also complexity in the settings of CML treatment.
Areas Covered: Different definitions of intolerance have been used through several clinical trials, making the published data non homogenous.